Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis

Abstract

GLP-1 receptor agonists have emerged as important therapeutic agents for type 2 diabetes mellitus (T2DM), but their comparative efficacy and broader applications remain subjects of ongoing research. The aim of the study was to evaluate and compare the efficacy, safety, and clinical applications of three GLP-1 receptor agonists – Semaglutide, Dulaglutide, and Exenatide – through systematic review and meta-analysis. A comprehensive search of PubMed/MEDLINE, Embase, Cochrane Library, Scopus, and Web of Science (2015–2023) identified 20 randomized controlled trials and observational studies. Primary outcomes included changes in HbA1c and body weight. Risk of bias was assessed using the Cochrane Collaboration’s Risk of Bias tool. Semaglutide demonstrated superior efficacy with mean HbA1c reduction of 1.45% and weight loss of 1.44 kg. Dulaglutide showed consistent reductions in HbA1c (1.1%) and weight (1.2 kg). while Exenatide exhibited moderate effects. Meta-analysis revealed a significant pooled effect estimate favoring GLP-1 receptor agonists. with a mean HbA1c difference of –0.81 (95% CI: –0.92 to –0.70). Gastrointestinal side effects were most common, with Semaglutide showing the highest incidence. This meta-analysis establishes Semaglutide as the most effective GLP-1 receptor agonist for glycemic control and weight reduction, while Dulaglutide and Exenatide offer viable alternatives with fewer side effects. These findings support evidence-based decision-making in T2DM management and highlight the potential broader therapeutic applications of GLP-1 receptor agonists beyond diabetes care.

Keywords

obesity - GLP-1 - Ozempic - semaglutide - weight management

Publication History

Received: 20 October 2024

Accepted after revision: 17 March 2025

Article published online:
23 May 2025

• References

• 1 Johnson AB, Smith CD, Thompson EF. Expanding applications of GLP-1 receptor agonists beyond glycemic control. Diabetes Care 2020; 43: 2698-2707
• 2 Nauck MA, Meier JJ, Cavender MA. et al. Cardiovascular actions and clinical outcomes with GLP-1 receptor agonists and DPP-4 inhibitors. Circulation 2019; 139: 2738-2750
• 3 American Diabetes Association. Standards of medical care in diabetes-2023. Diabetes Care 2023; 46: S1-S668
• 4 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71
• 5 Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab 2021; 12: 2042018821997320
• 6 Falagas ME, Pitsouni EI, Malietzis GA. et al. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. FASEB J 2008; 22: 338-342
• 7 Higgins JPT, Thomas J, Chandler J. et al. Cochrane handbook for systematic reviews of interventions version 6.2. Cochrane. 2021 www.training.cochrane.org/handbook
• 8 Ouzzani M, Hammady H, Fedorowicz Z. et al. Rayyan–a web and mobile app for systematic reviews. Syst Rev 2016; 5: 210
• 9 Sterne JAC, Savović J, Page MJ. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898
• 10 Borenstein M, Hedges LV, Higgins JPT. et al. Introduction to meta-analysis. New York: Wiley; 2009: 187-203
• 11 DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials 2015; 45: 139-145
• 12 Higgins JPT, Thompson SG, Deeks JJ. et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
• 13 Frías JP, Guja C, Hardy E. et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2016; 4: 1004-1016
• 14 Pratley RE, Aroda VR, Lingvay I. et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 2018; 6: 275-286
• 15 Lingvay I, Catarig AM, Frias JP. et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol 2019; 7: 834-844
• 16 Ahmann AJ, Capehorn M, Charpentier G. et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care 2018; 41: 258-266
• 17 Müller TD, Finan B, Bloom SR. et al. Glucagon-like peptide 1 (GLP-1). Mol Metab 2019; 30: 72-130
• 18 Armstrong MJ, Gaunt P, Aithal GP. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387: 679-690
• 19 Blackman A, Foster GD, Zammit G. et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes 2016; 40: 1310-1319
• 20 Mansur RB, Ahmed J, Salvadore G. et al. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study. J Affect Disord 2017; 207: 114-120
• 21 Marso SP, Bain SC, Consoli A. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834-1844
• 22 Andreadis P, Karagiannis T, Malandris K. et al. Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab 2018; 20: 2255-2263
• 23 Davies MJ, Aroda VR, Collins BS. et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022; 45: 2753-2786
• 24 Nauck MA, Quast DR, Wefers J. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab 2021; 46: 101102
• 25 Capehorn MS, Catarig AM, Furberg JK. et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab 2020; 46: 100-109
• 26 Bettge K, Kahle M, Abd El Aziz MS. et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab 2017; 19: 336-347
• 27 Newsome PN, Buchholtz K, Cusi K. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021; 384: 1113-1124
• 28 Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018; 27: 740-756
• 29 Wilding JPH, Batterham RL, Calanna S. et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384: 989-1002
• 30 Sorli C, Harashima S-I, Tsoukas GM. et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 2017; 5: 251-260
• 31 Ahrén B, Masmiquel L, Kumar H. et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet 2017; 5: 341-354
• 32 Jain A, Kanters S, Khurana R. et al. Real-world effectiveness analysis of switching from liraglutide or dulaglutide to semaglutide in patients with type 2 diabetes mellitus: the retrospective REALISE-DM study. Diabetes Ther 2021; 12: 527-536
• 33 Okamoto A, Yokokawa H, Nagamine T. et al. Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists. J Diabetes Metab Disord 2021; 20: 2021-2028
• 34 Selvarajan O, Subramanian R. A peptide in a pill - oral semaglutide in the management of type 2 diabetes. Diabetes Metab Syndr Obes 2023; 16: 1709-1720
• 35 Berra C, Rossi MC, Mirani M. et al. Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: a retrospective, cohort study (Sema-MiDiab01). Front Endocrinol 2023; 13: 1-15
• 36 Edwards KL, Minze MG. Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes. Core Evidence 2015; 10: 11-21
• 37 Katsuyama H, Hakoshima M, Umeyama S. et al. Real-world efficacy of glucagon-like peptide-1 (GLP-1) receptor agonist, dulaglutide, on metabolic parameters in Japanese patients with type 2 diabetes: a retrospective longitudinal study. Biomedicines 2023; 11: 869
• 38 Onishi Y, Ishii H, Oura T. et al. Efficacy and safety of once-weekly dulaglutide in type 2 diabetes patients using insulin: exploratory subgroup analysis by insulin regimen. Diabetes Therapy 2020; 11: 735-745
• 39 Patel S, Munir K, Sutherland S. et al. Efficacy of dulaglutide as a first injectable option for patients with type 2 diabetes: a post-hoc pooled analysis. Diabetes Ther 2019; 10: 2321-2330
• 40 Nagaike MOH, Kohata Y, Hiromura M. et al. Effect of dulaglutide versus liraglutide on glucose variability, oxidative stress, and endothelial function in type 2 diabetes: a prospective study. Diabetes Therapy 2019; 20: 215-228
• 41 Matfin G, Brunt KV, Zimmermann AG. et al. Safe and effective use of the once weekly dulaglutide single-dose pen in injection-naïve patients with type 2 diabetes. J Diabetes Sci Technol 2015; 9: 1071-1079
• 42 Loughlin AM, Qiao Q, Nunes AP. et al. Effectiveness and tolerability of therapy with once-weekly exenatide versus basal insulin among injectable-naive patients with type 2 diabetes in a real-world setting in the United States. Diabetes Spectrum 2018; 31: 129-137
• 43 Yin W, Di G, Zhou L. et al. Comments on: time-varying pattern of recurrence risk for Chinese breast cancer patients. Breast Cancer Res Treat 2009; 116: 209-210
• 44 Triplitt C. Managing diabetes in patients with diabetes of long duration. Diabetes Educ 2012; 38: 235-315
• 45 Mentz RJ, Thompson VP, Aguilar D. et al. Effect of once-weekly exenatide on clinical outcomes in patients with preexisting cardiovascular disease. Circulation 2018; 138: 2576-2578
• 46 Saunders WB, Nguyen H. Kalsekar et al. Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study. Diabetes Metab Syndr Obes 2016; 9: 217-223
• 47 Heimbürger SM, Brønden A, Johansen NJ. et al. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes. Expert Opin Pharmacother 2019; 20: 501-510
• 48 Abdul-Ghani MA, Migahid O, Megahed A. et al. Efficacy of exenatide plus pioglitazone versus basal/bolus insulin in T2DM patients with very high HbA1c levels. J Clin Endocrinol Metab 2017; 102: 2162-2170